Last reviewed 2026-06-02 · How we verify

eslicarbacepine

Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud · Phase 2 active Small molecule ✓ Verified Jun 2026

eslicarbacepine is a Small molecule drug developed by Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud. It is currently in Phase 2 development.

Eslicarbacepine is a medication used to study epilepsy in clinical trials. It is being investigated for its potential impact on lipid metabolism and cardiovascular risk factors in a clinical trial.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	eslicarbacepine
Sponsor	Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Impact of Eslicarbazepine Acetate on Lipid Metabolism and Cardiovascular Risk Factors

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

eslicarbacepine CI brief — competitive landscape report
eslicarbacepine updates RSS · CI watch RSS
Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud portfolio CI

Frequently asked questions about eslicarbacepine

What is eslicarbacepine?

eslicarbacepine is a Small molecule drug developed by Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud.

Who makes eslicarbacepine?

eslicarbacepine is developed by Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud (see full Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud pipeline at /company/andalusian-initiative-for-advanced-therapies-fundaci-n-p-blica-andaluza-progreso).

What development phase is eslicarbacepine in?

eslicarbacepine is in Phase 2.

Manufacturer: Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing